必须声明标量变量 "@Script_ID"。 肠道菌群失衡对同种异体造血干细胞移植的影响-《赣南医学院学报》

[1]谢景春,谢保平,余丽梅.肠道菌群失衡对同种异体造血干细胞移植的影响[J].赣南医学院学报,2020,40(06):588-593+603.[doi:10.3969/j.issn.1001-5779.2020.06.012]
 XIE Jing-chun,XIE Bao-ping,YU Li-mei.Effects of intestinal microbiota imbalance on allogeneic hematopoietic stem cells transplantation[J].,2020,40(06):588-593+603.[doi:10.3969/j.issn.1001-5779.2020.06.012]
点击复制

肠道菌群失衡对同种异体造血干细胞移植的影响()
分享到:

《赣南医学院学报》[ISSN:1001-5779/CN:36-1154/R]

卷:
40
期数:
2020年06期
页码:
588-593+603
栏目:
综述
出版日期:
2020-07-22

文章信息/Info

Title:
Effects of intestinal microbiota imbalance on allogeneic hematopoietic stem cells transplantation
文章编号:
1001-5779(2020)06-0588-07
作者:
谢景春1谢保平2余丽梅3
1.于都县人民医院,江西 于都 342300; 2.赣南医学院心脑血管疾病防治教育部重点实验室,江西 赣州 341000; 3.遵义医科大学附属医院贵州省细胞工程重点实验室,贵州省生物治疗人才基地,贵州 遵义 563003
Author(s):
XIE Jing-chun1 XIE Bao-ping2 YU Li-mei3
1.The People's Hospital of Yudu County, Yudu, Jiangxi 342300; 2.Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases of Ministry of Education, Gannan Medical University, Ganzhou, Jiangxi 341000; 3.Key Laboratory of Cel
关键词:
肠道菌群 同种异体造血干细胞移植 移植物抗宿主病 炎症 感染
Keywords:
Intestinal microbiome Allogeneic hematopoietic stem cell transplant Graft-versus-host disease Inflammation Infection
分类号:
R457.7
DOI:
10.3969/j.issn.1001-5779.2020.06.012
文献标志码:
A
摘要:
同种异体造血干细胞移植是治愈血液系统恶性肿瘤和其它多种疾病的重要手段,移植并发症是导致受者死亡的主要原因。受者长期使用免疫抑制剂、抗菌药物和其他化学治剂,可导致肠道菌群发生重大变化,极大地影响造血干细胞移植并发症的发生。本文从菌群多样性、细菌数量变化、细菌移位、基因改变和调节并发症相关免疫机制等方面,综述了肠道菌群失衡与同种异体造血干细胞移植并发症移植物抗宿主病和炎症感染发生、发展的密切关系; 阐述了包括饮食、益生元、益生菌及抗生素和粪菌移植在内,多种肠道菌群保护策略对同种异体造血干细胞移植并发症的有效治疗作用,为精准检测和有效防治同种异体干细胞移植并发症提供了新思路和理论依据。
Abstract:
Allogeneic hematopoietic stem cell transplantation is an important means to cure malignant tumors of the blood system and many other diseases. Transplantation complications are the leading main cause of death among recipients. Long-term use of immunosuppressants, antimicrobial agents and other chemical agents in recipients can lead to significant changes in intestinal microbiome, so that greatly affect the occurrence of hematopoietic stem cell transplantation complications. This paper summarizes the close relationship between intestinal microbiome imbalance and the occurrence and development of allogeneic hematopoietic stem cell transplantation complications, graft-versus host disease and inflammatory infection from the aspects of diversity of bacteria, change of bacterial quantity, bacterial translocation, gene change and immune mechanism related to regulating complications. The effective therapeutic effects of various intestinal microbiome protection strategies, including diet, prebiotics, probiotics, antibiotics and fecal bacteria transplantation, on the complications of allogeneic hematopoietic stem cell transplantation were expounded. It will provide new ideas and theoretical basis for accurate detection and effective prevention and treatment of complications of allogeneic stem cells transplantation.

参考文献/References:

[1] MARCHESI JR, ADAMS DH, FAVA F, et al. The gut microbiota and host health: a new clinical frontier[J]. Gut, 2016,65(2):330-339.
[2] CHUNG H, PAMP SJ, HILL JA, et al. Gut immune maturation depends on colonization with a host-specific microbiota[J]. Cell, 2012,149(7):1578-1593.
[3] DUBILIER N, MCFALL-NGAI M, ZHAO L. Microbiology: Create a global microbiome effort[J]. Nature, 2015,526(7575):631-634.
[4] SHONO Y, DOCAMPO MD, PELED JU, et al. Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice[J]. Sci Transl Med, 2016,8(339):339ra71.
[5] VAN BEKKUM DW, ROODENBURG J, HEIDT PJ, et al. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora[J]. J Natl Cancer Inst, 1974,52(2):401-404.
[6] JENQ RR, UBEDA C, TAUR Y, et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation[J]. J Exp Med, 2012,209(5):903-911.
[7] DOKI N, SUYAMA M, SASAJIMA S, et al. Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation[J]. Ann Hematol, 2017,96(9):1517-1523.
[8] HOLLER E, BUTZHAMMER P, SCHMID K, et al. Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease[J]. Biol Blood Marrow Transplant, 2014,20(5):640-645.
[9] TAUR Y, JENQ RR, PERALES MA, et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation[J]. Blood, 2014,124(7):1174-1182.
[10] TAUR Y, XAVIER JB, LIPUMA L, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation[J]. Clin Infect Dis, 2012,55(7):905-914.
[11] SCHWAB L, GORONCY L, PALANIYANDI S, et al. Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage[J]. Nat Med, 2014,20(6):648-654.
[12] JENQ RR, TAUR Y, DEVLIN SM, et al. Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease[J]. Biol Blood Marrow Transplant, 2015,21(8):1373-1383.
[13] LEVINE JE, HUBER E, HAMMER ST, et al. Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortality[J]. Blood, 2013,122(8):1505-1509.
[14] VIAUD S, SACCHERI F, MIGNOT G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide[J]. Science, 2013,342(6161):971-976.
[15] RAYES A, MORROW AL, PAYTON LR, et al. A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation[J]. Biol Blood Marrow Transplant, 2016,22(3):418-422.
[16] AL NZ, DIETRICH G, HUGOT JP, et al. Nod2: The intestinal gate keeper[J]. PLoS Pathog, 2017,13(3):e1006177.
[17] YAN H, BALDRIDGE MT, KING KY. Hematopoiesis and the bacterial microbiome[J]. Blood, 2018,132(6):559-564.
[18] PIPER C, DROBYSKI WR. Inflammatory Cytokine Networks in Gastrointestinal Tract Graft vs. Host Disease[J]. Front Immunol, 2019,10:163.doi: 10.3389/fimmu.2019.00163.
[19] KOLHO KL, KORPELA K, JAAKKOLA T, et al. Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation[J]. Am J Gastroenterol, 2015,110(6):921-930.
[20] GEVERS D, KUGATHASAN S, DENSON LA, et al. The treatment-naive microbiome in new-onset Crohn's disease[J]. Cell Host Microbe, 2014,15(3):382-392.
[21] AGHA A, SEHGAL A, LIM MJ, et al. Peri-transplant clostridium difficile infections in patients undergoing allogeneic hematopoietic progenitor cell transplant[J]. Am J Hematol, 2016,91(3):291-294.
[22] ANDERMANN TM, REZVANI A, BHATT AS. Microbiota Manipulation With Prebiotics and Probiotics in Patients Undergoing Stem Cell Transplantation[J]. Curr Hematol Malig Rep, 2016,11(1):19-28.
[23] BUFFIE CG, BUCCI V, STEIN RR, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile[J]. Nature, 2015,517(7533):205-208.
[24] JAIN T, CROSWELL C, URDAY-CORNEJO V, et al. Clostridium Difficile Colonization in Hematopoietic Stem Cell?Transplant Recipients: A Prospective Study of the Epidemiology and Outcomes Involving Toxigenic and Nontoxigenic Strains[J]. Biol Blood Marrow Transplant, 2016,22(1):157-163.
[25] MATHEWSON ND, JENQ R, MATHEW AV, et al. Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease[J]. Nat Immunol, 2016,17(5):505-513.
[26] TOMKOVICH S, JOBIN C. Microbiota and host immune responses: a love-hate relationship[J]. Immunology, 2016,147(1):1-10.
[27] PETERSSON J, SCHREIBER O, HANSSON GC, et al. Importance and regulation of the colonic mucus barrier in a mouse model of colitis[J]. Am J Physiol Gastrointest Liver Physiol, 2011,300(2):327-333.
[28] MORTHA A, CHUDNOVSKIY A, HASHIMOTO D, et al. Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis[J]. Science, 2014,343(6178):1249288.
[29] FUCHS A, VERMI W, LEE JS, et al. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-γ-producing cells[J]. Immunity, 2013,38(4):769-781.
[30] HAZENBERG MD, SPITS H. Human innate lymphoid cells[J]. Blood, 2014,124(5):700-709.
[31] LINDEMANS CA, CALAFIORE M, MERTELSMANN AM, et al. Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration[J]. Nature, 2015,528(7583):560-564.
[32] NARUSHIMA S, SUGIURA Y, OSHIMA K, et al. Characterization of the 17 strains of regulatory T cell-inducing human-derived Clostridia[J]. Gut Microbes, 2014,5(3):333-339.
[33] ZEISSIG S, BLUMBERG RS. Commensal microbial regulation of natural killer T cells at the frontiers of the mucosal immune system[J]. FEBS Lett, 2014,588(22):4188-4194.
[34] MARTIN-GALLAUSIAUX C, LARRAUFIE P, JARRY A, et al. Butyrate Produced by Commensal Bacteria Down-Regulates Indolamine 2,3-Dioxygenase 1(IDO-1)Expression via a Dual Mechanism in Human Intestinal Epithelial Cells[J]. Front Immunol, 2018,9:2838.
[35] PETERSON LW, ARTIS D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis[J]. Nat Rev Immunol, 2014,14(3):141-153.
[36] LEMAL R, CABRESPINE A, PEREIRA B, et al. Could enteral nutrition improve the outcome of patients with haematological malignancies undergoing allogeneic haematopoietic stem cell transplantation? A study protocol for a randomized controlled trial(the NEPHA study)[J]. Trials, 2015,16:136.
[37] IYAMA S, SATO T, TATSUMI H, et al. Efficacy of Enteral Supplementation Enriched with Glutamine, Fiber, and Oligosaccharide on Mucosal Injury following Hematopoietic Stem Cell Transplantation[J]. Case Rep Oncol, 2014,7(3):692-699.
[38] RINGDéN O, REMBERGER M, HOLMBERG K, et al. Many days at home during neutropenia after allogeneic hematopoietic stem cell transplantation correlates with low incidence of acute graft-versus-host disease[J]. Biol Blood Marrow Transplant, 2013,19(2):314-320.
[39] TAUR Y, JENQ RR, UBEDA C, et al. Role of intestinal microbiota in transplantation outcomes[J]. Best Pract Res Clin Haematol, 2015,28(2-3):155-161.
[40] WEBER D, OEFNER PJ, DETTMER K, et al. Rifaximin preserves intestinal microbiota balance in patients undergoing allogeneic stem cell transplantation[J]. Bone Marrow Transplant, 2016,51(8):1087-1092.
[41] SHONO Y, VAN DEN BRINK MRM. Empiric antibiotic use in allogeneic hematopoietic cell transplantation: should we avoid anaerobe coverage?[J]. Blood Adv, 2017,1(25):2325-2328.
[42] DENIS B, LAFAURIE M, DONAY JL, et al. Prevalence, risk factors, and impact on clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteraemia: a five-year study[J]. Int J Infect Dis, 2015,39:1-6.
[43] WEBER D, JENQ RR, PELED JU, et al. Microbiota Disruption Induced by Early Use of Broad-Spectrum Antibiotics Is an Independent Risk Factor of Outcome after Allogeneic Stem Cell Transplantation[J]. Biol Blood Marrow Transplant, 2017,23(5):845-852.
[44] XIE Y, CHEN H, ZHU B, et al. Effect of intestinal microbiota alteration on hepatic damage in rats with acute rejection after liver transplantation[J]. Microb Ecol, 2014,68(4):871-880.
[45] GORSHEIN E, WEI C, AMBROSY S, et al. Lactobacillus rhamnosus GG probiotic enteric regimen does not appreciably alter the gut microbiome or provide protection against GVHD after allogeneic hematopoietic stem cell transplantation[J]. Clin Transplant, 2017,31(5):e12947.
[46] DEFILIPP Z, PELED JU, LI S, et al. Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity[J]. Blood Adv, 2018,2(7):745-753.
[47] KAKIHANA K, FUJIOKA Y, SUDA W, et al. Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut[J]. Blood, 2016,128(16):2083-2088.

相似文献/References:

[1]谢 华,何良梅,刘 瑶,等.肠道菌群与炎症性肠病[J].赣南医学院学报,2017,37(04):659.[doi:10.3969/j.issn.1001-5779.2017.04.050]
 XIE Hua,HE Liang-mei,LIU Yao,et al.Gut Microbiota and Inflammatory Bowel Diseases[J].,2017,37(06):659.[doi:10.3969/j.issn.1001-5779.2017.04.050]
[2]谢 园,#,陈玲霞,等.肠道菌群在宿主抗柠檬酸杆菌感染中的作用和机制[J].赣南医学院学报,2019,39(10):973.[doi:10.3969/j.issn.1001-5779.2019.10.001]
 XIE Yuan,CHEN Ling-xia,LIU Yu-xia,et al.The role of gut microbiota in host resistance against Citrobacter rodentium infection[J].,2019,39(06):973.[doi:10.3969/j.issn.1001-5779.2019.10.001]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金项目(81260507); 贵州省科技重大专项项目[黔科合重大专项字(2011)6002]; 江西省教育厅项目(GJJ180809)
通信作者:谢保平,男,硕士,助理实验师,研究方向:中药抗骨质疏松机制研究。E-mail:m18932446096-1@163.com
余丽梅,女,博士,教授,研究方向:干细胞治疗学研究。E-mail:ylm720@sina.com
更新日期/Last Update: 2020-07-30